GILD Stock: This Could Be a Big Problem for Gilead Sciences, Inc. Gilead Sciences, Inc. (NASDAQ:GILD) stock is a heavyweight in the biotech space; the company bolsters a $105.0-billion market cap and ranks high among its competitors like GlaxoSmithKline plc(NYSE:GSK) and Pfizer Inc. (NYSE:PFE). The biotech space has been known to make and break many
Complete Reading

Create Account



Log In Your Account